Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.42 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 2/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937984 | 1.00 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1937313 | 1.00 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1938682 | 1.00 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1937656 | 1.00 | SPHK2 (0.42) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL1205488 | 0.98 | SPHK2 (0.39) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL8070978 | 0.96 | SPHK2 (0.38) | SPHK2SPHK1DNM1ZDHHC20ZDHHC2 | |
| SCHEMBL20361795 | 0.92 | GRIN2D (0.37) | SPHK2SPHK1NOS3NOS1NOS2 | |
| SCHEMBL1505132 | 0.90 | — | — | |
| SCHEMBL19371464 | 0.84 | — | — | |
| SCHEMBL9238513 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117379391-A | Compositions and methods of treatment | 蓝莓疗法有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117017925-A | Compositions and methods of treatment | 蓝莓疗法有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-111808886-B | In vitro or ex vivo methods for promoting the entry of an introduced agent into a cell | 泰克里亚有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-111808886-A | In vitro or ex vivo methods for promoting the entry of introduced agents into cells | 泰克里亚有限公司 | 2020-10-23 | — | — | CN | disclosed |
| CN-103957942-B | Method of producing a composite material | 皇家兽医学院 | 2020-05-22 | — | — | CN | disclosed |
| CN-105377250-B | Compositions and methods for combating antibacterial resistant bacteria | 蓝莓疗法有限公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-105579028-B | Antifungal topical compositions and methods of treatment | 蓝莓疗法有限公司 | 2020-03-20 | — | — | CN | disclosed |
| CN-102993057-B | Synthesis method of 1,6-bis(cyano-guanidino) hexane | GANSU RES INST OF CHEMICAL INDUSTRY | 2014-09-17 | — | — | CN | disclosed |
| CN-102993057-A | Synthesis method of 1,6-bis(cyano-guanidino) hexane | GANSU RES INST OF CHEMICAL INDUSTRY | 2013-03-27 | — | — | CN | disclosed |
| EP-1574503-B1 | 2,4-Diamino-1,3,5-triazine derivative | HAMARI CHEMICALS LTD (JP) | 2013-03-13 | — | — | EP | disclosed |
| US-7622469-B2 | 2,4-diamino-1,3,5-triazine derivatives | HAMARI CHEMICALS, LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060154928-A1 | Novel 2,4-diamino-1,3,5-triazine derivative | HAMARI CHEMICALS, LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1574503-A1 | NOVEL 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVE | Hamari Chemicals Co., Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| US-6916958-B2 | Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions | ALCON MANUFACTURING, LTD. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1042007-B1 | AMINOBIGUANIDES AND THE USE THEREOF TO DISINFECT CONTACT LENSES AND PRESERVE PHARMACEUTICAL COMPOSITIONS | ALCON LAB INC (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040063791-A1 | Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions | ALCON RESEARCH, LTD. | 2004-04-01 | — | — | US | disclosed |
| US-6664294-B1 | Compounds which have excellent antimicrobial activity, even at very low concentrations, and which is retained in presence of salt-containing media, such as saline solutions | ALCON MANUFACTURING, LTD. | 2003-12-16 | — | — | US | disclosed |
| EP-1042007-A2 | AMINOBIGUANIDES AND THE USE THEREOF TO DISINFECT CONTACT LENSES AND PRESERVE PHARMACEUTICAL COMPOSITIONS | Alcon Laboratories, Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032158-A2 | AMINOBIGUANIDES TO DISINFECT CONTACT LENSES AND PRESERVE PHARMACEUTICAL COMPOSITIONS | ALCON LABORATORIES, INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154928-A1 | Novel 2,4-diamino-1,3,5-triazine derivative | DAZAP1, DCUN1D5, TLR5 | SPHK2 3230/4885SPHK1 3530/4885DNM1 1145/4885 |
| US-20040063791-A1 | Aminobiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions | AASDHPPT, ALAD, AAAS | SPHK2 4571/4885SPHK1 4522/4885DNM1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.